Back to Top

Who we are

The multidisciplinary consortium of N2B-patch brings together Universities, Research institutes, SMEs and Industry with complementary distinct expertise out of chemical, biological, regulatory and business areas. We are partners from eight European countries: Belgium, Czech Republic, France, Germany, Greece, Italy, Switzerland and the UK.

The consortium benefit from an intensive exchange with the European Medicines Agency, with patients as well as the expertise of healthcare professionals.

Below you will find more information about the individual partners forming the N2B-patch team:







Advisory Board


Bild ist nicht verfügbar
Bild ist nicht verfügbar
Bild ist nicht verfügbar
Bild ist nicht verfügbar
Bild ist nicht verfügbar
Bild ist nicht verfügbar
Bild ist nicht verfügbar
Bild ist nicht verfügbar
Bild ist nicht verfügbar

Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB, based in Germany

Fraunhofer is one of Europe's leading organisations in the field of applied research and technology development. It is a non-profit organisation comprising 67 individual institutes in Germany. The Institute leading Fraunhofer’s N2B-patch project involvement is the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB). IGB are experts in innovative interfacial engineering technologies. IGB employs over 315 people, primarily scientists and engineers. In response to the growing complexity of demand, the Fraunhofer IGB combines various technical processes under the aspects of material and energy efficiency. With regard to technical realization, IGB has established a large variety of methods, which involve either films being deposited from the gas phase or the precipitation of thin films or particles from the liquid phase.



Contipro a.s, based in Czech Republic

Contipro Inc. is an SME that was set up in 1994. Its activities focus on the production of active substances for applications in cosmetics and medicine, with a specific focus on viscous solutions and hydrogels. Contipro has earned a reputation as one of the most advanced centres in the field of hyaluronan-related chemistry and biology. It was published 79 scientific publications in last 10 years and has submitted 68 patent applications within the holding. Most of Contipro’s research and development is conducted in its own laboratories. The laboratories are divided into 15 research groups comprising research and development in wound healing, tissue engineering, carriers of drugs, nanoparticles, nanofibers and microfibers preparation. There is also a specialised group focussed on medical devices development.




MyBiotech GmbH, based in Germany

MyBiotech is a CDMO offering end to end development, manufacturing services and innovative products for biotech and pharma. MyBiotech`s mission is bringing biotechnology and pharmaceutical products into the market in a fast and efficient way. Furthermore, the company aims to become leading partner in biotechnology and pharmaceutical research and development, manufacturing, and processing in Europe and beyond. At MyBiotech innovative technologies are brought to be a part of the solution bringing projects one step closer to success. Current products are realised by green technologies such as production of omega-3 fatty acids from algae. Innovative, more efficient pharmaceuticals are already identified for the short-term pipeline. In order to be able to offer contract manufacturing to the pharmaceutical sector, a GMP certification and establishment of a new GMP-compliant manufacturing site will serve to fill the gap for bringing the formulations with innovative character to the market.


Hochschule Biberach, based Germany

The Biberach University of Applied Science (HBC) was founded in 1964 and the faculty for Biotechnology, in 2006. The Faculty of Biotechnology (BT) and the Institute for Applied Biotechnology (IAB) are located at the Campus Aspach in Biberach (Germany). They complete the majors „pharmaceutical biotechnology“ and „industrial biotechnology“ with matching research programs. IAB was founded in 2007.The research and development consist of interdisciplinary processes across the biopharmaceutical value chain and raw material processing using industrial biotechnology: Protein design, process engineering, process optimization, analytic, formulation, QA, also enzymatic and biocatalytical processes in order to obtain renewable resources. Hence, the core competence of the institute is the manufacturing process of biopharmaceuticals as well as products of the industrial biotechnology. The laboratories of IAB represent the whole biotechnological manufacturing process, starting from the establishment of cell lines and microorganisms for fermentation, protein purification and –analytics.


Centre for Research and Technology Hellas – CERTH, based in Greece

The Centre for Research and Technology - Hellas (CERTH) was founded in March 2000. It is a private-law legal, non-profit organization, under the supervision of the General Secretariat for Research and Technology. The mission of CERTH is to carry out basic and applied research with emphasis on the development of new products and services with industrial, economic and social impact. The Chemical Process and Energy Resources Institute (CPERI) is one of the four research institutes of CERTH. It focuses on fundamental and applied research that meets the specific technological needs of both Greek and European industries, for example regarding advanced production systems for petrochemical processes, reformulated fuels and hydrocarbons, catalytic processes, energy and environmental technologies and processes. Its Laboratory of Polymer Reaction Engineering (LPRE) was established in 1985 and carries out innovative, collaborative research work with an emphasis on advanced multi-scale modeling of chemical and biological systems, functional materials, novel micro- and nano-encapsulation technologies, and more.


Beiter GmbH & Co. KG , based in Germany

The small and medium sized company Beiter was founded in 1937 and currently employs about 70 employees. The majority of 56 employees is working in the fabrication department, 7 employees work in administration, 5 in construction and 2 in programming. Company Beiter’s main products are tools they build for plastic parts, especially for rear and head lamps in the automotive industry. More and more, company Beiter also builds molds for other market sections and for the medical industry. In general, company Beiter’s production facilities and staff are capable to produce molds from 3D Data until the finished tools. This reflects that their in-house production depth is very high. Sizes of the tools range from 200 kg to 30 tons. Beiter also offers in-house molding of the tools, making use of their molding machines designed from 80 tons to 750 tons.

Furthermore, Beiter is highly experienced in 3D printing. They are able to produce certain parts via the rapid prototyping technique using the FDM- (Focused Deposition Modelling) and Inkjet- (High resolution acrylic resin print with inkjet print heads) method.


Laboratorio Europeo di Spettroscopie Non Lineari, based in Italy

The European Laboratory for Non Linear Spectroscopy (LENS) was established in 1991 at the University of Florence as an independent scientific research centre with a clear international vocation, aimed to promote and facilitate the exchange of ideas, scientific themes, and technical skills. Since the beginning, LENS has been associated with universities and research centres, both Italian and foreign, public and private, by means of agreements. The main ones are with the University of Florence and with the Italian National Research Council (CNR). LENS is part of the National Research Infrastructure Roadmap as one of the most important interdisciplinary research institution in Italy such as advanced laser and spectroscopic facilities open to researchers from European countries. LENS has been actively involved in research under the EC Framework Programs since FP3, in particular FP5, FP6 and FP7 (Cooperation, People, Capacities and Ideas). LENS is a partner of the Human Brain Project.


JensonR+ Limited, based in United Kingdom)

JensonR+ was formed in 2011, through a joint venture with a regulatory consultancy and is today a specialist consultancy offering a global range of services and in-house expertise covering the entire product lifecycle from early development through to post-marketing. The clients of JensonR+ range from small innovators and entrepreneurs, through to Blue Chip corporations, and come from different sectors, such as from the human and veterinary pharmaceutical, cosmetics, foods, devices, herbals and legal industries. The specialist team of Jenson R+ is experienced in regulatory affairs, product development, quality assurance, drug safety, medical information, copy approval, project management, training and market access.


LGI Consulting Sàrl, based in France

LGI is a French consultancy, founded in 2005. It offers a wide range of consulting services to support its clients’ decision-making with a strategy base. The firm’s strategic marketing approach is based on insights into both advanced technological developments and novel business models, with innovation at the heart of the process. LGI’s approach combines the analysis of technological development with market and social drivers to support customers with a global innovation approach. LGI’s services include market research and forecasts, global industry analysis and stakeholder mapping. LGI has developed a recognised expertise in business modelling, technologies and market assessments. The company has a positioning in high tech sectors: energy, transport, security, ICT, health and environment. LGI’s approach is usually multidisciplinary and European (its consultants have competences in law, finance, engineering, chemistry, IT and are fluent in French, English, German, Spanish and Czech).


The European Multiple Sclerosis Platform aisbl, based in Belgium

Founded in 1989, the European Multiple Sclerosis Platform (EMSP) is the umbrella organisation for 40 Multiple Sclerosis (MS) societies from 35 European countries. EMSP represents their interests at the European level and works to achieve its goals of high quality equitable treatment and support for persons with multiple sclerosis throughout Europe. En route to its ultimate vision of a world without multiple sclerosis, EMSP will work on a three pillar approach to ensure that people with MS have a real voice in determining their own objectives and priorities. The EMSP team is engaged in advocacy and awareness-raising campaigns to influence European decision-makers and EU policy-makers; they gather and provide knowledge and expertise to relevant stakeholders and encourage high quality research and the dissemination of excellent, evidence-based information on MS.


Department of Neurology, Experimental Neurology Center, Neuroimmunology/ Multiple Sclerosis University Hospital Bern, based in Switzerland

The Department of Neurology with its state-of-the art laboratories in the Experimental Neurology Center (ZEN) is the largest neurological department in Switzerland. We are committed to clinical, translational and basic research as the basis for innovation and future development of medicine, and aim to combine clinical practice with basic research in a multidisciplinary fashion. The Neuroimmunology/Multiple sclerosis group merges basic research with translational and clinical/paraclinical approaches. A particular interest lies in the mechanisms of autoimmune inflammatory responses of the central nervous system with a special focus on glial and T-cell biology. The identification of potential molecular and paraclinical/clinical markers for detection of disease progression and the assessment of the benefit-risk profile under immunotherapy also follows a translational approach with biological samples from different clinical studies.


Don't have an account yet? Register Now!

Sign in to your account